The passage of a sweeping US healthcare reform measure appears to be on shaky ground with the election of Republican Scott Brown as Senator from Massachusetts1.
Both the Senate and House versions of the healthcare reform bill contain numerous provisions of interest to pharmaceutical companies, such as introducing a regulatory pathway for biosimilars, imposing an annual fee of $2...
Please login to read the full article.
